Clinical Trial Update: a Study in Subjects With Otoferlin Mutation-related Hearing Loss Using RNA Base-eDiting Therapy(SOUND) [EARLY_Phase 1]

View source ↗

Summary

The EARLY_PHASE1 trial of RNA Base-eDiting Therapy (SOUND) for otoferlin-related congenital hearing loss has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Otoferlin-related Hearing Loss

Drugs mentioned

• RNA Base-eDiting Therapy (SOUND)

Snippet

Sponsor: HuidaGene Therapeutics Co., Ltd. | Conditions: Congenital Hearing Loss | EARLY_Phase 1 | Status: WITHDRAWN